1,752 reports of this reaction
1.8% of all DILTIAZEM HYDROCHLORIDE reports
#10 most reported adverse reaction
ATRIAL FIBRILLATION is the #10 most commonly reported adverse reaction for DILTIAZEM HYDROCHLORIDE, manufactured by Bausch Health US LLC. There are 1,752 FDA adverse event reports linking DILTIAZEM HYDROCHLORIDE to ATRIAL FIBRILLATION. This represents approximately 1.8% of all 97,371 adverse event reports for this drug.
Patients taking DILTIAZEM HYDROCHLORIDE who experience atrial fibrillation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ATRIAL FIBRILLATION is a less commonly reported adverse event for DILTIAZEM HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to atrial fibrillation, the following adverse reactions have been reported for DILTIAZEM HYDROCHLORIDE:
The following drugs have also been linked to atrial fibrillation in FDA adverse event reports:
ATRIAL FIBRILLATION has been reported as an adverse event in 1,752 FDA reports for DILTIAZEM HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ATRIAL FIBRILLATION accounts for approximately 1.8% of all adverse event reports for DILTIAZEM HYDROCHLORIDE, making it a notable side effect.
If you experience atrial fibrillation while taking DILTIAZEM HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.